(Q33462220)

English

Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

author name string

P M Parreiras

1

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

L A Sirota

2

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

L D Wagner

3

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

S L Menzies

4

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

J L Arciniega

5

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

language of work or name

0 references

publication date

6 June 2009

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

4537-4542

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Anthrax in Europe: its epidemiology, clinical characteristics, and role in bioterrorism

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Endemic, Notifiable Bioterrorism-Related Diseases, United States, 1992–1999

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Iraq's biological weapons. The past as future?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Bioterrorism preparedness and response: clinicians and public health agencies as essential partners

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Biodefense R&D: anticipating future threats, establishing a strategic environment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum-containing adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Anthrax vaccine: evidence for safety and efficacy against inhalational anthrax

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Safety of anthrax vaccine: a review by the Anthrax Vaccine Expert Committee (AVEC) of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Validation of the anthrax lethal toxin neutralization assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Measuring agreement in method comparison studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Development of an in vitro-based potency assay for anthrax vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

A concordance correlation coefficient to evaluate reproducibility

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Measurement in Medicine: The Analysis of Method Comparison Studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Immunization against anthrax with Bacillus anthracis protective antigen combined with adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

Studies on immunity in anthrax. X. Gel-adsorbed protective antigen for immunization of man.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of parallelism and nonparallelism in bioassay dilution curves.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.045

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.05.045

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33462220&oldid=1607182027"